Correction
4/22/2013

A summary in the April 15 edition of AANP SmartBrief gave the incorrect name of the drug that showed the lowest risk of new-onset diabetes for participants in a meta-analysis. The name of the drug is pravastatin. SmartBrief regrets the error.

Related Summaries